This qualitative research study was conducted to develop a novel, comprehensive, patient-reported outcome measure (PRO), the "Symptoms and Impacts of Androgen Deprivation Therapy (ADT) for Prostate Cancer" (SIADT-PC), assessing hormonal therapy-related symptoms and their impacts on men with advanced prostate cancer.
Concept elicitation (CE) interviews were conducted among adult men with prostate cancer to evaluate their experiences with ADT. Based on key symptom and impact concepts mentioned, an initial PRO measure was developed. The draft measure was further assessed in cognitive debriefing (CD) interviews with men with prostate cancer, in which participants reviewed items, response options, and recall periods. Initial item-based psychometric analyses were conducted using interview data. The draft questionnaire was revised on the basis of participant feedback, quantitative psychometric results, and consultation with clinical experts.
A total of 21 participants were interviewed (CE concept elicitation, n = 12; CD cognitive debriefing, n = 17; n = 8 completed both). Mean participant age (SD) was 59.7 (8.7) years and 76.2% were white. The de novo SIADT-PC measure consists of 27 items: 11 symptoms (e.g., fatigue, hot flashes, and erectile dysfunction), 2 long-term symptoms (e.g., weight gain), 10 impacts (e.g., impacts on physical activities and relationships), and 4 related to mode of administration (i.e., injection-site reactions). Items were assessed with a 5-point verbal rating scale, with answer choices that capture frequency or severity.
Once fully validated, this de novo measure may be used in clinical studies and clinical practice to assess hormone therapy-related symptoms and impacts, enabling physicians to identify timely and appropriate interventions.
Advances in therapy. 2024 Jun 11 [Epub ahead of print]
Ashley Ross, Kelsie Brewer, Stacie Hudgens, Bruce Brown, Mark Fallick, Simon de Paauw-Holt, Bhakti Arondekar, Jennifer Clegg, Elke Hunsche
Northwestern Feinberg School of Medicine, Chicago, IL, USA., Clinical Outcomes Solutions, Chicago, IL, USA., Clinical Outcomes Solutions, Tucson, AZ, USA., Myovant Sciences Inc, Brisbane, CA, USA., Sumitomo Pharma Switzerland GmbH, Aeschengraben 27, 4051, Basel, Switzerland., Pfizer, Inc, Collegeville, PA, USA., Sumitomo Pharma Switzerland GmbH, Aeschengraben 27, 4051, Basel, Switzerland. .